Prevalence, characteristics, and associated risk factors of drug consumption and chemsex use among individuals attending an STI clinic (EpITs STUDY).

Marta Rosas Cancio-Suárez, Raquel Ron, Jorge Díaz-Álvarez, Javier Martínez-Sanz, Sergio Serrano-Villar, Santiago Moreno, Matilde Sánchez-Conde
Author Information
  1. Marta Rosas Cancio-Suárez: Department of Infectious Diseases, Hospital Ramón y Cajal, Carretera de Colmenar, Madrid, Spain.
  2. Raquel Ron: Department of Infectious Diseases, Hospital Ramón y Cajal, Carretera de Colmenar, Madrid, Spain.
  3. Jorge Díaz-Álvarez: Department of Infectious Diseases, Hospital Ramón y Cajal, Carretera de Colmenar, Madrid, Spain.
  4. Javier Martínez-Sanz: Department of Infectious Diseases, Hospital Ramón y Cajal, Carretera de Colmenar, Madrid, Spain.
  5. Sergio Serrano-Villar: Department of Infectious Diseases, Hospital Ramón y Cajal, Carretera de Colmenar, Madrid, Spain.
  6. Santiago Moreno: Department of Infectious Diseases, Hospital Ramón y Cajal, Carretera de Colmenar, Madrid, Spain.
  7. Matilde Sánchez-Conde: Department of Infectious Diseases, Hospital Ramón y Cajal, Carretera de Colmenar, Madrid, Spain.

Abstract

Sex-related drug consumption and its health-related consequences have gained relevance in the assessment of patients with sexually transmitted infections (STIs), which pose a significant challenge to public health. We aim to assess the prevalence and characteristics of drug consumption and chemsex practices, describe the associated risk factors among general individuals attending an STI clinic, and evaluate the psychological impact associated with these behaviors. We conducted an online anonymous survey offered to patients with a diagnosis of STI in a tertiary hospital in Spain. Data included sociodemographic characteristics, sexual preferences and behavior, and assessment of drug use, chemsex, and psychological and mental health symptoms. Data from 145 subjects was collected, with a higher proportion of cis-gender men (71%), and a median age of 32 years. 64 participants (44%) reported drug use in the last year, with an observed 33.8% prevalence of chemsex consumption. Drug use and chemsex were more frequent among cis-gender men, Men who have Sex with Men (MSM), people living with HIV (PLHIV), and those reporting previous group sex. Poppers and cannabis were the most frequently reported drugs, with a prevalence close to 20% for cocaine, mephedrone, extasis, and GHB. Consequences related to drug use included unpleasant physical sensations, sexual dysfunction, and impaired sexual experience after reduction or drug discontinuation. The prevalence of drug use and chemsex practices are high among patients evaluated for STIs, especially between men, MSM, and subjects practicing group sex. The study highlights the urgent need for targeted interventions on prevention and reduction of their impact on health and social well-being.

Keywords

References

  1. Int J Drug Policy. 2019 Jan;63:74-89 [PMID: 30513473]
  2. Int J STD AIDS. 2023 Dec;34(14):1034-1041 [PMID: 37608639]
  3. Int J Drug Policy. 2015 Dec;26(12):1171-6 [PMID: 26298332]
  4. Sex Transm Infect. 2021 Jun;97(4):282-289 [PMID: 33452129]
  5. Sex Health. 2019 Feb;16(1):18-24 [PMID: 30517838]
  6. Lancet HIV. 2022 Oct;9(10):e717-e725 [PMID: 35926550]
  7. Sex Transm Infect. 2018 Jun;94(4):268-276 [PMID: 28974552]
  8. AIDS Patient Care STDS. 2018 Mar;32(3):112-118 [PMID: 29620925]
  9. Int J STD AIDS. 2020 Nov;31(13):1238-1246 [PMID: 32996867]
  10. J Gay Lesbian Ment Health. 2013 Jan 11;17(1):96-102 [PMID: 23504693]
  11. Int J Drug Policy. 2018 May;55:231-241 [PMID: 29402683]
  12. Sex Transm Infect. 2017 May;93(3):203-206 [PMID: 27519259]
  13. AIDS Behav. 2023 Oct;27(10):3206-3212 [PMID: 36964835]
  14. Behav Sci (Basel). 2022 Dec 15;12(12): [PMID: 36546999]
  15. J Sex Med. 2021 Dec;18(12):1955-1969 [PMID: 34756552]
  16. J Sex Med. 2019 Nov;16(11):1758-1762 [PMID: 31447385]
  17. Dialogues Clin Neurosci. 2022 Jun 1;23(1):39-43 [PMID: 35860173]
  18. Gen Hosp Psychiatry. 2003 Jul-Aug;25(4):277-83 [PMID: 12850660]
  19. Front Psychiatry. 2020 Nov 13;11:584548 [PMID: 33281645]
  20. PLoS One. 2019 Dec 4;14(12):e0220272 [PMID: 31800575]
  21. J Sex Med. 2022 Aug;19(8):1210-1213 [PMID: 35501254]
  22. Int J Drug Policy. 2019 Jun;68:54-61 [PMID: 30999243]
  23. Indian J Psychol Med. 2020 Oct 13;42(6):575-576 [PMID: 33354086]
  24. Sex Transm Dis. 2018 May;45(5):325-331 [PMID: 29465683]
  25. Sex Transm Infect. 2023 Mar;99(2):97-103 [PMID: 35523571]

MeSH Term

Male
Humans
Adult
Homosexuality, Male
Prevalence
Sexual and Gender Minorities
Sexually Transmitted Diseases
Substance-Related Disorders
Risk Factors

Word Cloud

Created with Highcharts 10.0.0drugchemsexuseprevalenceconsumptionhealthamongsexualpatientscharacteristicsassociatedriskfactorsSTImenassessmentsexuallytransmittedinfectionsSTIspracticesindividualsattendingclinicpsychologicalimpactDataincludedsubjectscis-genderreportedMenMSMgroupsexreductioninterventionsSex-relatedhealth-relatedconsequencesgainedrelevanceposesignificantchallengepublicaimassessdescribegeneralevaluatebehaviorsconductedonlineanonymoussurveyoffereddiagnosistertiaryhospitalSpainsociodemographicpreferencesbehaviormentalsymptoms145collectedhigherproportion71%medianage32 years64participants44%lastyearobserved338%DrugfrequentSexpeoplelivingHIVPLHIVreportingpreviousPopperscannabisfrequentlydrugsclose20%cocainemephedroneextasisGHBConsequencesrelatedunpleasantphysicalsensationsdysfunctionimpairedexperiencediscontinuationhighevaluatedespeciallypracticingstudyhighlightsurgentneedtargetedpreventionsocialwell-beingPrevalenceEpITsSTUDY

Similar Articles

Cited By